Back to results
US 2022/0031714 A1Published application
Modified release doxycycline composition
AssigneeGalderma Holding SA
InventorsAnkit BAHETI, Bijay Kumar PADHI, Rajeev Singh RAGHUVANSHI
Life of this patent
Estimating the term…
Abstract
Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
Claims17
1-11. (canceled)
A method of treating inflammatory rosacea or an inflammatory symptom of either rosacea or acne vulgaris comprising administering to a human patient in need thereof a modified release oral composition comprising:
- (i) about 30 to less than about 50 mg of doxycycline, based on the equivalent weight of doxycycline base, wherein the doxycycline is in an amount of about 15-20% w/w;
- (ii) about 10-18% w/w of one or more water soluble and insoluble polymers;
- and
- (iii) about 1-20% w/w of one or more pharmaceutically acceptable excipients;
- wherein the composition is free of any immediate release component;
- and wherein the composition provides at least one of the following pharmacokinetic parameters:
- (a) average input rate of about 4 ng/hr/mL to about 15 ng/hr/mL during a time period of T0 min to T30 min, and
- (b) average input rate of about 15 ng/hr/mL to about 40 ng/hr/mL during a time period of T0 min to T60 min.
5 more elements
Dependencies are inferred from the claim text.